Search results for "ADULT"

showing 10 items of 17453 documents

Serological and virological evidence of non-sexual transmission of human herpesvirus type 8 (HHV8).

2000

To evaluate whether or not human herpesvirus 8 (HHV8) can be transmitted through a non-sexual route a serological survey was carried out in a group of 51 catholic nuns. The seroprevalence rate and the geometrical mean antibody titre to anti-latent HHV8 antigen were similar in nuns and in a group of 60 women, matched by age, in the general population (27 vs. 24%; 1028 vs. 1575, respectively). Moreover, by using nested polymerase chain reaction (PCR), HHV8 DNA sequences were detected in 7 of 16 (43·8%) saliva and peripheral blood mononuclear cells (PBMC) from patients with classical Kaposi's sarcoma (KS) and in 3 out of 7 (42%) AIDS-KS patients. None of 5 HIV positive persons who did not have…

Sexually transmitted diseaseAdultSalivaSexual transmissionEpidemiologyPopulationBiologyPolymerase Chain Reactionlaw.inventionSerologylawSeroepidemiologic StudiesDisease Transmission InfectiousSeroprevalenceHumanseducationSalivaPolymerase chain reactionAgedAged 80 and overeducation.field_of_studyvirus diseasesHerpesviridae InfectionsMiddle AgedVirologyInfectious DiseasesImmunologyDNA ViralHerpesvirus 8 HumanFemaleNested polymerase chain reactionResearch Article
researchProduct

Low rate of oral human papillomavirus (HPV) infection in women screened for cervical HPV infection in Southern Italy: A cross-sectional study of 140 …

2009

Even though the natural history of cervical and oral human papillomavirus (HPV) infection has been investigated intensely, the possibility that HPV may infect both sites in the same subject is not well documented. This study investigated the frequency of concurrent oral and cervical HPV infection in southern Italian women, in the light of some selected socio-behavioral variables. One hundred forty women (mean age: 36 years), with known cervical HPV status, were analyzed for oral HPV. Age, smoking/drinking habits, clinical and socio-behavioral history were assessed by personal interviews. Oral mucosal cells were collected by oral brushing and HPV DNA was sought by the use of nested PCR ampli…

Sexually transmitted diseasecervical mucosaAdultsexually transmitted infection (STI)Cross-sectional studyConcordancePopulationCervix UteriPolymerase Chain ReactionYoung AdultRisk FactorsVirologyMedicineHumansYoung adultPapillomaviridaeeducationCervixPapillomaviridaeeducation.field_of_studyMouthbiologyoral mucosabusiness.industryPapillomavirus InfectionsHPV infectionSequence Analysis DNAMiddle Agedbiology.organism_classificationmedicine.diseaseVirologySettore MED/40 - Ginecologia E OstetriciaInfectious Diseasesmedicine.anatomical_structureCross-Sectional StudiesItalyDNA ViralHPV infectionFemaleoral–genital infectionbusinessJournal of medical virology
researchProduct

Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations

2013

Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associat…

Shiga-toxinGraft RejectionMaleDNA Primer030232 urology & nephrologyEscherichia coli InfectionGene mutationurologic and male genital diseasesGastroenterology0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesImmunology and AllergyPharmacology (medical)gene mutationKidney transplantationEscherichia coli Infections0303 health sciencesKidneymedicine.diagnostic_testShiga-Toxigenic Escherichia coliAntigens CD46Microangiopathic hemolytic anemiaMiddle AgedPrognosisfemale genital diseases and pregnancy complications3. Good healthPedigreemedicine.anatomical_structureComplement Factor IComplement factor I; gene mutation; hemolytic uremic syndrome; kidney transplantation; membrane cofactor protein; Shiga-toxin; Adult; Antigens CD46; Case-Control Studies; Complement Factor I; DNA Primers; Escherichia coli Infections; Female; Genetic Testing; Graft Rejection; Hemolytic-Uremic Syndrome; Heterozygote; Humans; Kidney Failure Chronic; Kidney Transplantation; Male; Middle Aged; Mutation; Pedigree; Prognosis; Recurrence; Risk Factors; Shiga-Toxigenic Escherichia coli; Thrombocytopenia; Young Adult; Transplantation; Immunology and Allergy; Pharmacology (medical)FemaleCase-Control StudieHumanAdultmedicine.medical_specialtyHeterozygotePrognosiComplement factor IMembrane Cofactor Protein03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Testing030304 developmental biologyGenetic testingDNA PrimersTransplantationbusiness.industryCD46Risk Factormedicine.diseaseKidney TransplantationThrombocytopeniaTransplantationCase-Control StudiesImmunologyHemolytic-Uremic SyndromeMutationhemolytic uremic syndromeKidney Failure ChronicbusinessAmerican Journal of Transplantation
researchProduct

Influence of custom-made and prefabricated insoles before and after an intense run

2017

[EN] Each time the foot contacts the ground during running there is a rapid deceleration that results in a shock wave that is transmitted from the foot to the head. The fatigue of the musculoskeletal system during running may decrease the ability of the body to absorb those shock waves and increase the risk of injury. Insoles are commonly prescribed to prevent injuries, and both custom-made and prefabricated insoles have been observed to reduce shock accelerations during running. However, no study to date has included a direct comparison of their behaviour measured over the same group of athletes, and therefore great controversy still exists regarding their effectiveness in reducing impact …

Shock waveMaleCritical Care and Emergency MedicinePhysiologylcsh:MedicineAccelerometerPathology and Laboratory MedicineMaterial FatigueRunning0302 clinical medicineMaterials PhysicsMedicine and Health SciencesTreadmillGroung Reaction Forcelcsh:ScienceMusculoskeletal SystemFatigueTrauma MedicineMultidisciplinaryPhysicsClassical MechanicsFoamShock (mechanics)Muscle FatiguePhysical SciencesLegsEngineering and TechnologyFemaleAnatomyShock AttenuationTraumatic InjuryResearch ArticleAdultmedicine.medical_specialtyMaterials by StructureMaterials ScienceSTRIDE03 medical and health sciencesAccelerationYoung AdultPhysical medicine and rehabilitationSigns and SymptomsDiagnostic MedicineTEORIA DE LA SEÑAL Y COMUNICACIONESmedicineHumansTibial Stress-FractureDamage Mechanicsbusiness.industryBiological Locomotionlcsh:RLimbs (Anatomy)Biology and Life Sciences030229 sport sciencesStride lengthShoesAthletesMusculoskeletal InjuryImpact loadingExercise Testlcsh:QFeet (Anatomy)ElectronicsAccelerometersbusiness030217 neurology & neurosurgery
researchProduct

Neck and Shoulder Muscle Activation Among Experienced and Inexperienced Pilots in +Gz Exposure

2017

Background The aim of the present study was to compare differences in electromyography (EMG) activation of the neck and shoulder muscles between groups of inexperienced and experienced pilots during controlled +Gz exposure in a centrifuge. Methods The subjects were volunteer cadets (inexperienced group) and lieutenants (experienced group) undergoing their first centrifuge training. The first group did not have any high performance aircraft (HPA) experience, while the latter one had a 1-yr experience of intense flying of HPA. During the centrifuge run, EMG activity was recorded from the left and right shoulder, neck flexor, and neck extensor muscles. Results The pilots without HPA experience…

Shoulderelectromyographymedicine.medical_specialtyhigh performance aircraftCentrifugationHypergravityElectromyographycervical spineYoung Adult03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationNeck MusclesHumHumansMedicine0501 psychology and cognitive sciences050102 behavioral science & comparative psychologyMuscle activityMuscle Skeletalta315VolunteerFinlandmedicine.diagnostic_testbusiness.industry05 social sciences030208 emergency & critical care medicineMuscle activationta3142General MedicineAnatomyShoulder muscleNeck musclesG forcePilotsMilitary PersonnelAerospace MedicineAviation medicinebusinessGravitationAerospace Medicine and Human Performance
researchProduct

Case report of necrotizing sialometaplasia

2010

Introduction: Necrotizing sialometaplasia is a rare inflammatory necrotizing reactive process that can involve minor and major salivary glands. Gland tissue ischaemia has been proposed as the aetiology. Case Report: A 21-year-old woman was referred with a 1-week history of bilateral painful swelling of the palate, with the development of two deep ulcers after the first 3 days. Ulcer edges were elevated but not indurated, and the bases had a necrotic appearance. An incisional biopsy of the margin of one ulcer confirmed the diagnosis of necrotizing sialometaplasia. The ulcers spontaneously healed within 8 weeks without treatment. Discussion: The clinical and histological similarity between th…

Sialometaplasia Necrotizingmedicine.medical_specialtyIncisional biopsyNecrotizing sialometaplasiabusiness.industryBenign lesion:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryYoung AdultOtorhinolaryngologyMajor Salivary GlandUNESCO::CIENCIAS MÉDICASEtiologyHumansMedicineFemaleSurgerybusinessGeneral Dentistry
researchProduct

Validation of the use of Actigraph GT3X accelerometers to estimate energy expenditure in full time manual wheelchair users with spinal cord injury.

2013

Study design: Cross-sectional validation study. Objectives: The goals of this study were to validate the use of accelerometers by means of multiple linear models (MLMs) to estimate the O2 consumption (VO2) in paraplegic persons and to determine the best placement for accelerometers on the human body. Setting: Non-hospitalized paraplegics’ community. Methods: Twenty participants (age=40.03 years, weight=75.8 kg and height=1.76 m) completed sedentary, propulsion and housework activities for 10 min each. A portable gas analyzer was used to record VO2. Additionally, four accelerometers (placed on the non-dominant chest, non-dominant waist and both wrists) were used to collect second-by-second a…

Signal processingAdultMalemedicine.medical_specialtyPercentileMean squared errormedia_common.quotation_subjectPopulationMonitoring AmbulatoryAccelerometerModels BiologicalAccelerationPhysical medicine and rehabilitationOxygen ConsumptionAccelerometrymedicineEvaluation methodologyHumanseducationSpinal Cord Injuriesmedia_commonParaplegiaeducation.field_of_studyVariablesbusiness.industryPhysical activityLinear modelGeneral MedicineMiddle AgedGas analyzerAccelerometerCross-Sectional StudiesNeurologyWheelchairsFemaleNeurology (clinical)businessMATEMATICA APLICADAEnergy MetabolismSpinal cord
researchProduct

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1)…

2014

Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens have a high pill burden and are associated with increased rates and severity of adverse events, such as anaemia and rash. The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection.In QUEST-1, a phase 3, randomise…

SimeprevirAdultMalemedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsDrug Administration ScheduleTelaprevirPolyethylene Glycolschemistry.chemical_compoundDouble-Blind MethodPegylated interferonSimeprevirBoceprevirInternal medicineRibavirinmedicineHumanschronic hepatitis CSulfonamidesbusiness.industryRibavirinvirus diseasesInterferon-alphaGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessHeterocyclic Compounds 3-Ringmedicine.drugPeginterferon alfa-2a
researchProduct

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluat…

2017

Background: Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. Aim: To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. Methods: Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centers. Results: Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. Genotype 3, bilirubin lev…

SimeprevirMaleGenetics and Molecular Biology (all)HepacivirusPediatricsGastroenterologyBiochemistry0302 clinical medicineAnimal Cells80 and overBileMedicinePublic and Occupational HealthProspective Studieslcsh:ScienceAged 80 and overAdult; Aged; Aged 80 and over; Antiviral Agents; Drug Therapy Combination; Female; Hepatitis C; Humans; Incidence; Liver Diseases; Male; Middle Aged; Prospective Studies; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Liver DiseaseIncidenceLiver DiseasesChild HealthBloodCirrhosisPhysical SciencesRegression Analysis030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesStatistics (Mathematics)Humanmedicine.medical_specialtyGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansStatistical MethodsAgedBlood CellsBiochemistry Genetics and Molecular Biology (all)Flaviviruseslcsh:ROrganismsBiology and Life Sciencesmedicine.diseaseRegimenProspective Studie030104 developmental biologychemistryAgricultural and Biological Sciences (all)lcsh:QMathematicsDevelopmental BiologyRNA viruses0301 basic medicineDAA HCV resistanceSofosbuvirPhysiologylcsh:MedicineLiver diseasechemistry.chemical_compoundMathematical and Statistical TechniquesMedicine and Health SciencesPathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CMedical microbiologyMiddle AgedHepatitis CBody FluidsVirusesCombinationFemaleAnatomyPathogensResearch Articlemedicine.drugPlateletsLedipasvirAdultDaclatasvirSettore MED/12 - GASTROENTEROLOGIAHCV liver diseases Cirrhosis DAA failureResearch and Analysis MethodsInternal medicineAntiviral Agentbusiness.industryViral pathogensBilirubinCell BiologyFibrosisHepatitis virusesMicrobial pathogensSurgeryLiver functionbusiness
researchProduct

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) …

2017

Background HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12. Methods This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simepre…

SimeprevirMalePsychologie appliquéeFetge - MalaltiesHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycols0302 clinical medicinelcsh:Science61 - MedicinaLiver DiseasesSciences bio-médicales et agricolesCirrhosisInterferonLiver Fibrosis030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadBiologieHumanmedicine.medical_specialtyCiències multidisciplinàriesGenotypeSaudi ArabiaAlpha interferon:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Gastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesHumansAgedMedicine and health sciencesHepaciviruFlavivirusesInterleukinslcsh:ROrganismsInterleukinmedicine.diseaseRegimen:Digestive System Diseases::Liver Diseases [DISEASES]chemistryImmunologylcsh:QMedicaments - AdministracióDevelopmental BiologyRNA viruseslcsh:Medicinemedicine.disease_cause:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Geographical Locationschemistry.chemical_compoundSimeprevirHospital Universitari Vall d’Hebron030212 general & internal medicinePathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CRecombinant ProteinMedical microbiologyMiddle AgedViral LoadHepatitis CRecombinant Proteins:enfermedades del sistema digestivo::enfermedades hepáticas [ENFERMEDADES]EuropeResearch DesignVirusesFemalePathogensResearch ArticleAdultAsiaAdolescentClinical Research DesignHepatitis C virusResearch and Analysis MethodsYoung AdultInternal medicineRibavirinmedicineddc:610Rapid Virologic ResponseAntiviral AgentBiology and life sciencesbusiness.industryRibavirinViral pathogensInterferon-alphaFibrosisHepatitis virusesMicrobial pathogensPeople and PlacesAdverse EventsInterferonsbusinessPLoS ONE
researchProduct